JAK Inhibitors

JAK1

JAK2

JAK3

Tyk2

JAK

JAK Inhibitors, Antagonists, Activators, Modulators, Inducers, Degraders & Ligands

Product Name	JAK1	JAK2	JAK3	Tyk2	JAK	Purity
Ruxolitinib	JAK1, IC₅₀: 3.3 nM	JAK2, IC₅₀: 2.8 nM	JAK3, IC₅₀: 428 nM	Tyk2, IC₅₀: 19 nM		99.99%
Tofacitinib	JAK1, IC₅₀: 112 nM	JAK2, IC₅₀: 20 nM	JAK3, IC₅₀: 1 nM			99.99%
Upadacitinib	JAK1, IC₅₀: 0.043 μM	JAK2, IC₅₀: 0.2 μM	JAK3, IC₅₀: 2.3 μM	Tyk2, IC₅₀: 4.7 μM		99.98%
Baricitinib	JAK1, IC₅₀: 5.9 nM	JAK2, IC₅₀: 5.7 nM	JAK3, IC₅₀: 560 nM	Tyk2, IC₅₀: 53 nM		99.97%
Deucravacitinib	JAK1, IC₅₀: 1 nM			Tyk2, IC₅₀: 0.2 nM		99.93%
PROTAC JAK1/2 degrader-1	JAK1, DC₅₀: 1.4 μM	JAK2, DC₅₀: 0.92 μM				99.47%
Fedratinib		JAK2, IC₅₀: 3 nM JAK2(V617F), IC₅₀: 3 nM				99.87%
Ruxolitinib phosphate	JAK1, IC₅₀: 3.3 nM	JAK2, IC₅₀: 2.8 nM	JAK3, IC₅₀: 428 nM	Tyk2, IC₅₀: 19 nM		99.97%
Tofacitinib citrate	JAK1, IC₅₀: 112 nM	JAK2, IC₅₀: 20 nM	JAK3, IC₅₀: 1 nM			99.94%
Pacritinib	JAK1, IC₅₀: 1280 nM	JAK2^V617F, IC₅₀: 19 nM JAK2^wt, IC₅₀: 23 nM	JAK3, IC₅₀: 520 nM	Tyk2, IC₅₀: 50 nM		99.93%
Ritlecitinib			JAK3, IC₅₀: 33.1 nM			99.80%
WP1066		JAK2				99.77%
Momelotinib	JAK1, IC₅₀: 11 nM	JAK2, IC₅₀: 18 nM	JAK3, IC₅₀: 155 nM			98.93%
Butyzamide		JAK2				99.83%
Abrocitinib	JAK1, IC₅₀: 29 nM	JAK2, IC₅₀: 803 nM		Tyk2, IC₅₀: 1253 nM		99.26%
Itacitinib	JAK1					99.97%
Filgotinib	JAK1, IC₅₀: 10 nM	JAK2, IC₅₀: 28 nM	JAK3, IC₅₀: 810 nM	Tyk2, IC₅₀: 116 nM		99.77%
Peficitinib	JAK1, IC₅₀: 3.9 nM	JAK2, IC₅₀: 5 nM	JAK3, IC₅₀: 0.7 nM	Tyk2, IC₅₀: 4.8 nM		99.43%
RO8191	JAK1					≥99.0%
AZD-1480	JAK1, IC₅₀: 1.3 nM	JAK2, IC₅₀: <0.4 nM				99.74%
Ruxolitinib (S enantiomer)					JAK	99.64%
Baricitinib phosphate	JAK1, IC₅₀: 5.9 nM	JAK2, IC₅₀: 5.7 nM	JAK3, IC₅₀: 560 nM	Tyk2, IC₅₀: 53 nM		99.97%
Golidocitinib	JAK1, IC₅₀: 73 nM					99.54%
CHZ868		JAK2, IC₅₀: 110 nM				98.69%
Cucurbitacin I		JAK2				99.56%
AT9283		JAK2, IC₅₀: 1.2 nM	JAK3, IC₅₀: 1.1 nM			99.67%
Brepocitinib	JAK1, IC₅₀: 17 nM	JAK2, IC₅₀: 77 nM	JAK3, IC₅₀: 6.9 μM			99.97%
Pyridone 6	Murine JAK1, IC₅₀: 15 nM	JAK2, IC₅₀: 1 nM	JAK3, IC₅₀: 5 nM	Tyk2, IC₅₀: 1 nM		98.20%
Fedratinib hydrochloride hydrate		JAK2, IC₅₀: 3 nM JAK2(V617F), IC₅₀: 3 nM				99.92%
Cerdulatinib	JAK1, IC₅₀: 12 nM	JAK2, IC₅₀: 6 nM	JAK3, IC₅₀: 8 nM	Tyk2, IC₅₀: 0.5 nM		99.06%
Delgocitinib	JAK1, IC₅₀: 2.8 nM	JAK2, IC₅₀: 2.6 nM	JAK3, IC₅₀: 13 nM	Tyk2, IC₅₀: 58 nM		99.61%
Gandotinib		JAK2, IC₅₀: 3 nM	JAK3, IC₅₀: 48 nM	Tyk2, IC₅₀: 44 nM		99.86%
Fezakinumab	JAK1					99.9%
BD750			JAK3			99.02%
Lestaurtinib		JAK2, IC₅₀: 0.9 nM				99.66%
Oclacitinib	JAK1, IC₅₀: 10 nM	JAK2, IC₅₀: 18 nM	JAK3, IC₅₀: 99 nM	Tyk2, IC₅₀: 84 nM		99.03%
NSC 42834		JAK2-WT, IC₅₀: 15 μM JAK2-V617F, IC₅₀: 28 μM
Londamocitinib	JAK1, IC₅₀: 0.54 nM					99.79%
JANEX-1			JAK3, IC₅₀: 78 μM			99.63%
Jolkinolide B					JAK	99.65%
Flonoltinib	JAK1, IC₅₀: 26 nM	JAK2, IC₅₀: 0.7 nM	JAK3, IC₅₀: 39 nM			99.48%
RGB-286638		JAK2, IC₅₀: 50 nM				99.70%
(E/Z)-Zotiraciclib		JAK2, IC₅₀: 73 nM				99.96%
Decernotinib	JAK1, Ki: 11 nM	JAK2, Ki: 13 nM	JAK3, Ki: 2.5 nM	Tyk2, Ki: 11 nM		99.91%
Oclacitinib monomaleate	JAK1, IC₅₀: 10 nM	JAK2, IC₅₀: 18 nM	JAK3, IC₅₀: 99 nM	Tyk2, IC₅₀: 84 nM		99.87%
Radotinib		JAK2				99.19%
SJ988497		JAK2				99.03%
VVD-118313	JAK1					99.47%
BMS-911543	JAK1, IC₅₀: 75 nM	JAK2, IC₅₀: 1.1 nM	JAK3, IC₅₀: 360 nM	Tyk2, IC₅₀: 66 nM		98.23%
SJ10542		JAK2, DC₅₀: 14 nM	JAK3, DC₅₀: 11 nM			99.32%
Atinvicitinib	JAK1	JAK2	JAK3			98.62%
Momelotinib sulfate	JAK1, IC₅₀: 11 nM	JAK2, IC₅₀: 18 nM	JAK3, IC₅₀: 155 nM			98.63%
CEP-33779		JAK2, IC₅₀: 1.8 nM	JAK3, IC₅₀: 150 nM			99.23%
Telocinobufagin		JAK2				99.93%
Broussonin E		JAK2				98.11%
NVP-BSK805	JAK1 JH1, IC₅₀: 31.63 nM	JAK2 JH1, IC₅₀: 0.48 nM FL JAK2 V617F, IC₅₀: 0.56 nM FL JAK2 wt, IC₅₀: 0.58 nM	JAK3 JH1, IC₅₀: 18.68 nM	TYK2 JH1, IC₅₀: 10.76 nM		99.30%
TG101209		JAK2, IC₅₀: 6 nM	JAK3, IC₅₀: 169 nM			98.81%
AZ960		JAK2, Ki: 0.45 nM JAK2, IC₅₀: <3 nM	JAK3, IC₅₀: 9 nM
Protosappanin A		JAK2				99.95%
Ilginatinib	JAK1, IC₅₀: 33 nM	JAK2, IC₅₀: 0.72 nM	JAK3, IC₅₀: 39 nM	Tyk2, IC₅₀: 22 nM		99.81%
Ivarmacitinib	JAK1	JAK2	JAK3	Tyk2		99.62%
SAR-20347	JAK1, IC₅₀: 23 nM	JAK2, IC₅₀: 26 nM	JAK3, IC₅₀: 41 nM	Tyk2, IC₅₀: 0.6 nM
Brepocitinib P-Tosylate	JAK1, IC₅₀: 17 nM	JAK2, IC₅₀: 77 nM	JAK3, IC₅₀: 6.9 μM			99.99%
XL019		JAK2, IC₅₀: 2.2 nM	JAK3, IC₅₀: 214.2 nM			99.65%
TCS 21311	JAK1, IC₅₀: 1.017 μM	JAK2, IC₅₀: 2.55 μM	JAK3, IC₅₀: 8 nM			99.49%
FM-381			JAK3, IC₅₀: 127 pM			98.08%
JAK2-IN-6		JAK2, IC₅₀: 22.86 μg/mL
BMS-986202				Tyk2 JH2, IC₅₀: 0.19 nM Tyk2 JH2, Ki: 0.02 nM		99.29%
PF-06263276	JAK1, IC₅₀: 2.2 nM	JAK2, IC₅₀: 23.1 nM	JAK3, IC₅₀: 59.9 nM	Tyk2, IC₅₀: 29.7 nM		≥99.0%
(R)-9b		JAK2		Tyk2		99.51%
Cadefrecitinib	JAK1, IC₅₀: 38 nM	JAK2, IC₅₀: 7.3 nM	JAK3, IC₅₀: 374 nM	Tyk2, IC₅₀: 2.3 nM		99.81%
Reticuline		JAK2				98.89%
(E/Z)-Zotiraciclib hydrochloride		JAK2				99.90%
Deuruxolitinib	JAK1	JAK2				99.18%
JAK-IN-23	JAK1, IC₅₀: 8.9 nM	JAK2, IC₅₀: 15 nM	JAK3, IC₅₀: 46.2 nM			98.88%
WHI-P97			JAK3, IC₅₀: 11 μM			99.16%
S6K1-IN-1			JAK3			99.71%
JAK2 JH2 binder-1		JAK2 JH2, Kd: 37.1 nM
G5-7		JAK2				98.45%
Desmethoxyyangonin		JAK2				99.00%
Graveoline	JAK1					99.93%
Lomedeucitinib				Tyk2		99.75%
Itacnosertib		JAK2, IC₅₀: 8540 nM				99.06%
RGB-286638 free base		JAK2, IC₅₀: 50 nM				98.09%
HG-7-85-01	JAK1, IC₅₀: 120 nM					98.14%
ZM39923 hydrochloride	JAK1, pIC₅₀: 4.4		JAK3, pIC₅₀: 7.1			99.84%
JAK3-IN-1	JAK1, IC₅₀: 896 nM	JAK2, IC₅₀: 1050 nM	JAK3, IC₅₀: 4.8 nM			99.31%
JAK3-IN-6			JAK3, IC₅₀: 0.15 nM			99.48%
Filgotinib maleate	JAK1, IC₅₀: 10 nM	JAK2, IC₅₀: 28 nM	JAK3, IC₅₀: 810 nM	Tyk2, IC₅₀: 116 nM		99.88%
NVP-BSK805 dihydrochloride	JAK1 JH1, IC₅₀: 31.63 nM	JAK2 JH1, IC₅₀: 0.48 nM FL JAK2 V617F, IC₅₀: 0.56 nM FL JAK2 wt, IC₅₀: 0.58 nM	JAK3 JH1, IC₅₀: 18.68 nM	TYK2 JH1, IC₅₀: 10.76 nM		99.36%
TCJL37				Tyk2, Ki: 1.6 nM		99.89%
Tyk2-IN-7				Tyk2 JH2, IC₅₀: 0.00053 μM Tyk2 JH2, Ki app: 0.00007 μM		99.58%
Cerdulatinib hydrochloride	JAK1, IC₅₀: 12 nM	JAK2, IC₅₀: 6 nM	JAK3, IC₅₀: 8 nM	Tyk2, IC₅₀: 0.5 nM		98.96%
Zotiraciclib		JAK2, IC₅₀: 13 nM				99.88%
(E/Z)-Zotiraciclib citrate		JAK2				99.83%
Modzatinib			JAK3
SJ1008030 formic		JAK2				98.91%
TyK2-IN-2				Tyk2 JH2, IC₅₀: 7 nM		99.05%
WHI-P154			JAK3, IC₅₀: 1.8 μM			98.77%
Tyk2-IN-5				Tyk2 JH2, Ki: 0.086 nM		99.35%
Quecitinib	JAK1			Tyk2		99.56%
JAK2-IN-7	JAK1, IC₅₀: 42 nM	JAK2, IC₅₀: 3 nM	JAK3, IC₅₀: 94 nM	Tyk2, IC₅₀: 75 nM		98.31%
Ritlecitinib tosylate			JAK3, IC₅₀: 33.1 nM			99.65%
Mulberrofuran G		JAK2
SC99		JAK2				98.90%
JAK1-IN-8	JAK1, IC₅₀: <500 nM	JAK2, IC₅₀: 500-1000 nM	JAK3, IC₅₀: >5000 nM
TYK2-IN-12	JAK1, Ki: 45.9 nM	JAK2, Ki: 21.93 nM	JAK3, Ki: 6.63 nM	Tyk2, Ki: 0.51 nM		98.81%
Ilginatinib hydrochloride	JAK1, IC₅₀: 33 nM	JAK2, IC₅₀: 0.72 nM	JAK3, IC₅₀: 39 nM	Tyk2, IC₅₀: 22 nM		98.92%
Envudeucitinibum	JAK1, IC₅₀: >30,000 nM	JAK2, IC₅₀: >30,000 nM	JAK3, IC₅₀: >30,000 nM	Tyk2, IC₅₀: 104-149 nM		99.56%
BI-1622			JAK3			98.02%
Itacnosertib hydrochloride		JAK2, IC₅₀: 8540 nM				99.43%
Methyl 6-(1-(4-methoxybenzyl)-1H-pyrazol-4-yl)-4-oxo-4,5-dihydropyrazolo[1,5-a]pyrazine-2-carboxylate	JAK1, IC₅₀: 21 nM	JAK2, IC₅₀: 8 nM	JAK3, IC₅₀: 1051 nM	Tyk2, IC₅₀: 6 nM		98.01%
Patiromer			JAK3, IC₅₀: 33.1 nM
GS-829845	JAK1					99.19%
(R,R)-VVD-118313	JAK1					99.34%
SJ1008030 TFA		JAK2				99.81%
2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide	JAK1, Ki: 0.7 nM	JAK2, Ki: 0.7 nM	JAK3, Ki: 0.4 nM	Tyk2, Ki: 4.8 nM		99.80%
JAK1/2-IN-1	JAK1, IC₅₀: 0.4 nM	JAK2, IC₅₀: 8.1 nM				98.36%
Solcitinib	JAK1, IC₅₀: 9.8 nM					99.51%
JAK-IN-20	JAK1, IC₅₀: 7 nM	JAK2, IC₅₀: 5 nM	JAK3, IC₅₀: 14 nM			99.63%
Ilginatinib maleate	JAK1, IC₅₀: 33 nM	JAK2, IC₅₀: 0.72 nM	JAK3, IC₅₀: 39 nM	Tyk2, IC₅₀: 22 nM		99.33%
JAK-IN-3	JAK1, IC₅₀: 5 nM	JAK2, IC₅₀: 70 nM	JAK3, IC₅₀: 3 nM	Tyk2, IC₅₀: 34 nM		98.92%
Flonoltinib TFA	JAK1, IC₅₀: 26 nM	JAK2, IC₅₀: 0.7 nM	JAK3, IC₅₀: 39 nM			98.94%
(2R,5S)-Ritlecitinib			JAK3, IC₅₀: 144.8 nM			99.77%
Phlorizin dihydrate		JAK2				99.51%
GLPG0634 analog	JAK1, IC₅₀: <100 nM	JAK2, IC₅₀: <100 nM	JAK3, IC₅₀: <100 nM	Tyk2, IC₅₀: <100 nM		98.07%
JAK2-IN-11		JAK2-WT, IC₅₀: ≤10 nM JAK2-V617F, IC₅₀: ≤10 nM				98.03%
YLIU-4-105-1		JAK2				99.39%
JAK/HDAC-IN-1	JAK1, IC₅₀: 4.8 nM	JAK2, IC₅₀: 4 nM	JAK3, IC₅₀: 7.4 nM	Tyk2, IC₅₀: 49 nM		98.63%
ZT55		JAK2, IC₅₀: 0.031 μM				99.51%
ON044580		JAK2-WT, IC₅₀: 1.23 μM JAK2-V617F, IC₅₀: 1.09 μM				99.11%
GSK2646264		JAK2, pIC₅₀: 5				98.39%
JAK1-IN-4	JAK1, IC₅₀: 85 nM	JAK2, IC₅₀: 12.8 μM				99.26%
SD-1029		JAK2
JAK1/2 ligand 1	JAK1	JAK2				99.91%
JAK 3i	JAK1, IC₅₀: 1520 nM	JAK2, IC₅₀: 8680 nM	JAK3, IC₅₀: 0.43 nM			99.81%
Blovacitinib	JAK1, IC₅₀: 3 nM	JAK2, IC₅₀: 37 nM	JAK3, IC₅₀: 1517 nM	Tyk2, IC₅₀: 36 nM		99.71%
Cyclanoline chloride		JAK2
ZM 449829	JAK1, pIC₅₀: 4.7		JAK3, pIC₅₀: 6.8			99.73%
Frevecitinib	JAK1	JAK2	JAK3	Tyk2
Itacitinib adipate	JAK1					99.18%
JAK2-IN-10		JAK2-V617F, IC₅₀: ≤10 nM
Mocravimod		JAK2				98.39%
DCZ3301		JAK2				99.73%
BMS-066				Tyk2, IC₅₀: 72 nM		99.09%
MJ04	JAK1, IC₅₀: 192.64 nM	JAK2, IC₅₀: 255.88 nM	JAK3, IC₅₀: 2.03 nM			98.08%
JAK-IN-21	JAK1, IC₅₀: 1.73 nM	JAK2, IC₅₀: 2.04 nM JAK2-V617F, IC₅₀: 109 nM		Tyk2, IC₅₀: 62.9 nM		99.72%
FM-479			JAK3			99.2%
JAK2/TYK2-IN-1		JAK2, IC₅₀: 157 nM		Tyk2, IC₅₀: 9 nM		99.94%
Dual Cathepsin L/JAK-IN-1	JAK1, IC₅₀: 337.1 nM	JAK2, IC₅₀: 5.251 nM	JAK3, IC₅₀: 27.29 nM	Tyk2, IC₅₀: 172.6 nM		98.47%
JAK-IN-11					JAK	98.62%
Ruxolitinib sulfate	JAK1, IC₅₀: 3.3 nM	JAK2, IC₅₀: 2.8 nM	JAK3, IC₅₀: 428 nM	Tyk2, IC₅₀: 19 nM
Bayer-18				Tyk2
Leucrose	JAK1					98.53%
JAK-IN-10					JAK	99.72%
SD-1008		JAK2				99.10%
Upadacitinib tartrate tetrahydrate	JAK1, IC₅₀: 0.043 μM	JAK2, IC₅₀: 0.2 μM	JAK3, IC₅₀: 2.3 μM	Tyk2, IC₅₀: 4.7 μM
Peficitinib hydrobromide	JAK1, IC₅₀: 3.9 nM	JAK2, IC₅₀: 5 nM	JAK3, IC₅₀: 0.7 nM	Tyk2, IC₅₀: 4.8 nM
RAI-20	JAK1, IC₅₀: 15.1 nM	JAK2, IC₅₀: 22.7 nM
JAK-IN-4					JAK
Ritlecitinib malonate			JAK3, IC₅₀: 33.1 nM
JAK3 covalent inhibitor-1			JAK3, IC₅₀: 11 nM
YYSW001	JAK1
NVP-BSK805 trihydrochloride	JAK1 JH1, IC₅₀: 31.68 nM	JAK2 JH1, IC₅₀: 0.48 nM JAK2(V617F), IC₅₀: 0.56 nM FL JAK2 wt, IC₅₀: 0.58 nM		TYK2 JH1, IC₅₀: 18.68 nM
AT9283 lactic acid		JAK2, : 1.2 nM	JAK3, : 1.1 nM
Nezulcitinib					JAK
Pacritinib hydrochloride	JAK1, IC₅₀: 1280 nM	JAK2^V617F, IC₅₀: 19 nM JAK2^wt, IC₅₀: 23 nM	JAK3, IC₅₀: 520 nM	Tyk2, IC₅₀: 50 nM
JAK-IN-36	JAK1, IC₅₀: 2.2 nM
YSY01A		JAK2
LRRK2-IN-8				Tyk2, IC₅₀: 10-100 nM
WYE-151650			JAK3
Tyk2-IN-3				Tyk2, IC₅₀: 485 nM
PROTAC FLT3/JAK2/BRD4 Degrader-1		JAK2, DC₅₀: 0.678 nM
TYK2 ligand 4				Tyk2
Tyk2-IN-16				Tyk2 JH2, IC₅₀: <10 nM
SB1578		JAK2, IC₅₀: 46 nM
MTP		JAK2
NUAK1-IN-3			JAK3, IC₅₀: 225 nM
JAK-2/3-IN-3		JAK2, IC₅₀: 13.00 nM	JAK3, IC₅₀: 14.86 nM
JAK-2/3-IN-1		JAK2, Ki: <250 nM	JAK3, Ki: <250 nM
DEL1187-126-28-16			JAK3, IC₅₀: 0.97 nM
Peficitinib hydrochloride	JAK1, IC₅₀: 3.9 nM	JAK2, IC₅₀: 5 nM	JAK3, IC₅₀: 0.7 nM	Tyk2, IC₅₀: 4.8 nM
JAK2-IN-15		JAK2, IC₅₀: 1.17 nM
EC-70124		JAK2
JAK-IN-30	JAK1, IC₅₀: 15 nM	JAK2, IC₅₀: 2 nM	JAK3, IC₅₀: 18 nM	Tyk2, IC₅₀: 2 nM
JAK1/STAT3-IN-1	JAK1
FAK-IN-22			JAK3, IC₅₀: 9.99 nM
JANEX-1 hydrochloride			JAK3, IC₅₀: 78 μM
BRD4-IN-41		JAK2, : 1.1
TYK2 ligand 1				Tyk2
JAK1-IN-20	JAK1, IC₅₀: <0.5 nM
EGFR-IN-178		JAK2, IC₅₀: 55.6 nM	JAK3, IC₅₀: 46.1 nM
WP1193		JAK2
Momelotinib dihydrochloride	JAK1	JAK2
Ten01	JAK1, IC₅₀: 5 nM
Thi-DPPY			JAK3, IC₅₀: 1.38 nM
JAK1/TYK2-IN-3	JAK1, IC₅₀: 37 nM	JAK2, IC₅₀: 140 nM	JAK3, IC₅₀: 362 nM	Tyk2, IC₅₀: 6 nM
PF-00956980	JAK1, IC₅₀: 2.2 μM	JAK2, IC₅₀: 23.1 μM	JAK3, IC₅₀: 59.9 μM
Tyk2-IN-20	JAK1, IC₅₀: <100 nM	JAK2, IC₅₀: <100 nM	JAK3, IC₅₀: <100 nM	Tyk2, IC₅₀: <5 nM
JAK3-IN-20			JAK3, IC₅₀: 0.7473 nM
Tubulosine	JAK1, IC₅₀: 69.5 nM	JAK2, IC₅₀: 84.9 nM	JAK3, IC₅₀: 9.9 nM	Tyk2, IC₅₀: 76.3 nM
Ovalicin		JAK2
JAK1/2-IN-3	JAK1, IC₅₀: 14.73 nM	JAK2, IC₅₀: 10.03 nM
TK4b		JAK2, IC₅₀: 19.40 nM	JAK3, IC₅₀: 18.42 nM
JAK2-IN-18		JAK2
JAK3-IN-9			JAK3, IC₅₀: 1.7 nM
JAK2-IN-13		JAK2, IC₅₀: 54.7 nM
PROTAC JAK2 degrader-1		JAK2-V617F, DC₅₀: 27.35 nM
LRRK2/NUAK1/TYK2-IN-1				Tyk2
JAK2-IN-1		JAK2
JAK3-IN-11	JAK1, IC₅₀: 1.32 μM	JAK2, IC₅₀: 1 μM	JAK3, IC₅₀: 1.7 nM
JAK2-IN-20		JAK2, IC₅₀: 49.17 nM
JAK2-IN-19		JAK2, Kd: 1.11 μM
JAK-2/3-IN-2		JAK2, IC₅₀: 23.85 nM	JAK3, IC₅₀: 18.9 nM
DPPY			JAK3, IC₅₀: <10 nM
JAK2-IN-16		JAK2^V617F
TYK2 ligand 2				Tyk2 JH2
JAK1/TYK2-IN-5	JAK1 JH2, Kd: 0.02 nM			TYK2 JH1, Kd: 0.0044 nM
JAK1-IN-18	JAK1, IC₅₀: 0.15 nM	JAK2, IC₅₀: 3.69 nM	JAK3, IC₅₀: 3.10 nM	Tyk2, IC₅₀: 1.49 nM
DEL1187-126-5-80			JAK3, IC₅₀: 7.9 nM
JAK2/FLT3-IN-3		JAK2, IC₅₀: 2.01 nM	JAK3, IC₅₀: 104.40 nM
AC-430		JAK2
JAK1-IN-12	JAK1, IC₅₀: 0.0246 μM	JAK2, IC₅₀: 0.423 μM	JAK3, IC₅₀: 0.410 μM	Tyk2, IC₅₀: 1.12 μM
K882	JAK1
JAK1-IN-14	JAK1, IC₅₀: 12.6 nM	JAK2, IC₅₀: 135 nM
Voderdeucitinib				Tyk2
JAK1-IN-9	JAK1, IC₅₀: 72 nM	JAK2, IC₅₀: 839 nM
WWQ-131	JAK1, IC₅₀: 647.35 nM	JAK2, IC₅₀: 2.56 nM	JAK3, IC₅₀: 528.61 nM	Tyk2, IC₅₀: 1298.13 nM
NVP-BVB808		JAK2, IC₅₀: 0.35 nM
Soficitinib		JAK2, IC₅₀: 1.2 nM		Tyk2, IC₅₀: 0.5 nM
JAK3 covalent inhibitor-2			JAK3, IC₅₀: 7.2 nM
MS-1020			JAK3
PJ27			JAK3, IC₅₀: 786 nM
JAK2-IN-9		JAK2
NSC 33994		JAK2, IC₅₀: 60 nM (JAK2 Val617Phe kinase activity )
JI6			JAK3, IC₅₀: ~250 nM
JAK3-IN-18	JAK1, IC₅₀: 8575 nM	JAK2, IC₅₀: 7431 nM	JAK3, IC₅₀: 0.5391 nM
JNK-IN-17	JAK1, IC₅₀: 0.039 μM		JAK3, IC₅₀: 0.079 μM
Tyk2-IN-22	JAK1, IC₅₀: 148.6 nM		JAK3, IC₅₀: 883.3 nM	Tyk2, IC₅₀: 9.7 nM
JAK-IN-39	JAK1, IC₅₀: 0.05 nM	JAK2, IC₅₀: 1.18 nM	JAK3, IC₅₀: 0.03 nM
JAK2-IN-21		JAK2, IC₅₀: 12.25 nM
JAK/HDAC-IN-2	JAK1, IC₅₀: 27.15 nM	JAK2, IC₅₀: 5.32 nM	JAK3, IC₅₀: 594.8 nM	Tyk2, IC₅₀: 414.4 nM
Deucravacitinib analog 1				Tyk2 JH2
JAK3/BTK-IN-6	JAK1, IC₅₀: >1000 nM	JAK2, IC₅₀: 657.9 nM	JAK3, IC₅₀: 0.4 nM	Tyk2, IC₅₀: >1000 nM
PI3K/Akt/mTOR-IN-7		JAK2
TK4g		JAK2, IC₅₀: 12.61 nM	JAK3, IC₅₀: 15.80 nM
JAK3-IN-17			JAK3, IC₅₀: 14.56 nM
JAK1-IN-10	JAK1
AUH-6-96			JAK3
JAK2/STAT3-IN-2		JAK2
JAK3-IN-14		JAK2, IC₅₀: 600 nM	JAK3, IC₅₀: 38 nM			99.32%
MRC-G-001	JAK1
Tyk2-IN-18				Tyk2 JH2, IC₅₀: <10 nM
JAK2-IN-17		FL JAK2 wt, IC₅₀: 160 nM FL JAK2 V617F, IC₅₀: 130 nM
PRN-371			JAK3
Jolkinolide B (Standard)					JAK
JAK2-IN-14	JAK1, IC₅₀: 179 nM	JAK2, IC₅₀: 2 nM	JAK3, IC₅₀: 161 nM	Tyk2, IC₅₀: 102 nM
oJak-989	JAK1, Ki: 2.8 nM
JAK3-IN-12	JAK1, IC₅₀: 18 nM	JAK2, IC₅₀: 42 nM	JAK3, IC₅₀: 9.5 nM
JAK1-IN-19	JAK1, IC₅₀: 0.02 nM	JAK2, IC₅₀: 0.5 nM	JAK3, IC₅₀: 91 nM	Tyk2, IC₅₀: 0.2 nM
Bufothionine		JAK2
Socrodeucitinib				Tyk2, IC₅₀: 1.41 nM
JAK1/2-IN-2	JAK1, Ki: 2 nM	JAK2, Ki: 0.6 nM
Tkip		JAK2
JAK2-IN-5		JAK2, IC₅₀: 0.078 μM JAK2^V617F, IC₅₀: 0.206 μM
JAK-IN-38	JAK1, IC₅₀: 0.44 μM	JAK2, IC₅₀: 0.12 μM	JAK3, IC₅₀: 0.06 μM	Tyk2, IC₅₀: 0.03 μM
JAK-IN-38	JAK1, IC₅₀: 0.44 μM	JAK2, IC₅₀: 0.12 μM	JAK3, IC₅₀: 0.06 μM	Tyk2, IC₅₀: 0.03 μM
JAK1/3-IN-1	JAK1, IC₅₀: 1.9 nM	JAK2, IC₅₀: 15 nM	JAK3, IC₅₀: 0.9 nM	Tyk2, IC₅₀: 25 nM
5TTU			JAK3
Pulchinenoside E2		JAK2				99.28%
Flonoltinib monomaleate	JAK1, IC₅₀: 26 nM	JAK2, IC₅₀: 0.7 nM	JAK3, IC₅₀: 39 nM
Momelotinib mesylate	JAK1, IC₅₀: 11 nM	JAK2, IC₅₀: 18 nM	JAK3, IC₅₀: 155 nM
ZM39923	JAK1, pIC₅₀: 4.4		JAK3, pIC₅₀: 7.1
NMS-P953		JAK2, IC₅₀: 0.008 μM
R-348 choline			JAK3
JAK3-IN-19			JAK3
NSC114792			JAK3
AS2553627	JAK1	JAK2	JAK3	Tyk2
TM-233		JAK2
JAK-IN-34	JAK1, IC₅₀: 0.40 nM	JAK2, IC₅₀: 0.83 nM	JAK3, IC₅₀: 2.10 nM	Tyk2, IC₅₀: 1.95 nM
JAK3-IN-7			JAK3, IC₅₀: 0.01 μM

Name
Email *

	Sorry, but the email address you supplied was invalid.